Dr. Stephanos Ioannidis obtained his B.Sc. at King's College London in chemistry and biochemistry before moving to Imperial College London where he received his PhD in organic chemistry under the supervision of Professor Donald Craig.? Following his PhD work, Dr. Ioannidis joined the laboratory of Professor Yoshito Kishi at Harvard University as a post-doctoral fellow. After completing his post-doctoral studies, he joined AstraZeneca in Waltham, MA. At AstraZeneca, he led several drug discovery teams at all stages of the pipeline, from target validation stages to the clinic.
In 2013, after more than 11 years of a successful career at AstraZeneca, Dr. Ioannidis moved to FORMA Therapeutics in Watertown, MA.? At FORMA Therapeutics, Dr. Ioannidis has been a leader within the protein homeostasis area and his current role is the Head of Early Portfolio covering the areas of oncology, immunology/inflammation and neuroscience.